Knechten H - Search Results

1

Safety and efficacy after switch to a saquinavir-containing antiretroviral regimen in protease inhibitor pretreated HIV-positive patients.

Stephan C, Jaeger H, Carganico A, Knecht G, Lutz T, Mayr C, Mosthaf FA, Koeppe S, Mueller M, Wolf E, Tappe A, Wellmann E, Knechten H. Stephan C, et al. Among authors: knechten h. Eur J Med Res. 2010 Sep 24;15(9):369-76. doi: 10.1186/2047-783x-15-9-369. Eur J Med Res. 2010. PMID: 20952345 Free PMC article.

2

Safety and efficacy of a saquinavir-containing antiretroviral regimen in previously ART-naïve or pretreated but protease inhibitor-naïve HIV-positive patients.

Knechten H, Stephan C, Mosthaf FA, Jaeger H, Lutz T, Cargnico A, Stoehr A, Koeppe S, Mayr C, Schewe K, Wolf E, Wellmann E, Tappe A. Knechten H, et al. Infection. 2010 Apr;38(2):108-16. doi: 10.1007/s15010-009-9249-x. Epub 2010 Mar 29. Infection. 2010. PMID: 20352287

3

The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naive and pre-treated but protease inhibitor (PI)-naive HIV-infected patients.

Knechten H, Stephan C, Mosthaf FA, Jaeger H, Carganico A, Lutz T, Schewe K, Mayr C, Wolf E, Wellmann E, Tappe A. Knechten H, et al. Eur J Med Res. 2011 Mar 28;16(3):93-100. doi: 10.1186/2047-783x-16-3-93. Eur J Med Res. 2011. PMID: 21486721 Free PMC article.

4

Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.

Salzberger B, Däumer M, Gute P, Jaeger H, Knechten H, van Lunzen J, Mauss S, Mayr C, Moll A, Plettenberg A, Rockstroh J, Staszewski S, Stellbrink HJ, Stoll M, Sturmer M. Salzberger B, et al. Among authors: knechten h. Eur J Med Res. 2007 Mar 26;12(3):93-102. Eur J Med Res. 2007. PMID: 17507306

5

Treatment during primary HIV infection does not lower viral set point but improves CD4 lymphocytes in an observational cohort.

Koegl C, Wolf E, Hanhoff N, Jessen H, Schewe K, Rausch M, Goelz J, Goetzenich A, Knechten H, Jaeger H, Becker W, Becker-Boost I, Berzow D, Beiniek B, Brust J, Shcuster D, Dupke S, Fenske S, Gellermann HJ, Gippert R, Hartmann P, Hintsche B, Jaeger H, Jaegel-Guedes E, Jessen H, Gölz J, Koelzsch J, Helm EB, Knecht G, Knechten H, Lochet I, Gute P, Mauruschat S, Mauss S, Miasnikov V, Mosthaf FA, Rausch M, Freiwald M, Reuter B, Schalk HM, Schappert B, Schnaitmann E, Schneider I, Schüler-Maué W, Schuler C, Seidel T, Starke W, Ulmer A, Müller M, Weitner I, Schewe K, Zamani C, Hanmond A, Ross K, Bottlaender A, Hoffmann C, Dix A, Schneidewind A, Lademann M; Ac-DAG Study Group. Koegl C, et al. Among authors: knechten h. Eur J Med Res. 2009 Jul 22;14(7):277-83. doi: 10.1186/2047-783x-14-7-277. Eur J Med Res. 2009. PMID: 19661009 Free PMC article.

6

Safety and Efficacy in HIV-1-Infected Patients Treated with Ritonavir-Boosted Saquinavir Mesylate.

Knechten H, Lutz T, Pulik P, Martin T, Tappe A, Jaeger H. Knechten H, et al. Arch Drug Inf. 2010 Mar;3(1):26-36. doi: 10.1111/j.1753-5174.2009.00028.x. Arch Drug Inf. 2010. PMID: 20428230 Free PMC article.

7

Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment.

Mauss S, Corzillius M, Wolf E, Schwenk A, Adam A, Jaeger H, Knechten H, Goelz J, Goetzenich A; DAGNA Lipantiretroviral therapy study group. Mauss S, et al. Among authors: knechten h. HIV Med. 2002 Jan;3(1):49-55. doi: 10.1046/j.1464-2662.2001.00100.x. HIV Med. 2002. PMID: 12059951 Free article.

8

[High incidence of non-AIDS-defined cancers among HIV-infected patients in Germany. A 3-year nationwide review].

Mosthaf FA, Hanhoff NJ, Goetzenich A, Wolf E, Knechten H. Mosthaf FA, et al. Among authors: knechten h. Dtsch Med Wochenschr. 2006 Aug 25;131(34-35):1849-52. doi: 10.1055/s-2006-949167. Dtsch Med Wochenschr. 2006. PMID: 16915544 German.

9

Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.

Wyen C, Hendra H, Siccardi M, Platten M, Jaeger H, Harrer T, Esser S, Bogner JR, Brockmeyer NH, Bieniek B, Rockstroh J, Hoffmann C, Stoehr A, Michalik C, Dlugay V, Jetter A, Knechten H, Klinker H, Skaletz-Rorowski A, Fätkenheuer G, Egan D, Back DJ, Owen A; German Competence Network for HIV/AIDS Coordinators. Wyen C, et al. Among authors: knechten h. J Antimicrob Chemother. 2011 Sep;66(9):2092-8. doi: 10.1093/jac/dkr272. Epub 2011 Jun 29. J Antimicrob Chemother. 2011. PMID: 21715435 Free article.

10

Efficacy and Safety of Switching to Dolutegravir With Boosted Darunavir in Virologically Suppressed Adults With HIV-1: A Randomized, Open-Label, Multicenter, Phase 3, Noninferiority Trial: The DUALIS Study.

Spinner CD, Kümmerle T, Schneider J, Cordes C, Heiken H, Stellbrink HJ, Krznaric I, Scholten S, Jensen B, Wyen C, Viehweger M, Lehmann C, Sprinzl M, Stoehr A, Bickel M, Jessen H, Obst W, Spornraft-Ragaller P, Khaykin P, Wolf E, Boesecke C; DUALIS Study Group. Spinner CD, et al. Open Forum Infect Dis. 2020 Aug 13;7(9):ofaa356. doi: 10.1093/ofid/ofaa356. eCollection 2020 Sep. Open Forum Infect Dis. 2020. PMID: 32965277 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

65 results

Search Page